Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 27.54
- Piotroski Score 2.00
- Grade Buy
- Symbol (CYBN)
- Company Cybin Inc.
- Price $11.62
- Changes Percentage (5.64%)
- Change $0.62
- Day Low $11.30
- Day High $12.95
- Year High $21.66
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/12/2025
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.22
- Trailing P/E Ratio -1.32
- Forward P/E Ratio -1.32
- P/E Growth -1.32
- Net Income $-78,080,000
Income Statement
Quarterly
Annual
Latest News of CYBN
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Cybin Inc. (CYBN) Stock Price, News, Quote & History - Yahoo Finance
Cybin Inc. has filed articles of amendment to consolidate its common shares, with one new share for every 38 existing shares. The company aims to revolutionize mental healthcare with innovative treatm...
By Yahoo! Finance | 1 month ago
